Golden
Circle Pharma

Circle Pharma

Biotechnology company developing cell permeable macrocyclic peptide therapeutics using an automated chemistry synthesis.

Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Computational structure-based design is combined with automated, fully synthetic chemistry. In the computational design workflow, large virtual libraries of diverse macrocycles for intrinsic cell permeability and target affinity are generated and screened. Circle Pharma’s technology allows them to target intracellular targets such as protein-protein interactions and achieve oral bioavailability. The automated chemistry synthesis is used to assess in parallel multiple design hypotheses for a given target and rapidly explore structure activity relationships. Circle Pharma is initially focused on intracellular protein-protein interactions that drive oncology pathways.

Timeline

January 17, 2018

Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.

Circle Pharma, Inc. today announced that results from its collaborative work with Pfizer Inc. to develop a potent and orally bioavailable macrocycle modulator of the chemokine receptor, CXCR7, have been published in the Journal of Medicinal Chemistry.

April 25, 2017

Circle Pharma Announces Expansion of Series A Financing and Appointment of James C. Lu to Its Board

Circle Pharma, Inc. today announced that it has completed an expansion of its Series A financing, with new investors WI Harper Group, Elements Partners, LLC, Whitesun Healthcare Ventures Limited and LifeForce Capital joining the round.

People

Name
Role
LinkedIn

David C. Spellmeyer, PhD

Interim Chief Scientific Officer



David J. Earp, J.D., Ph.D.

President, CEO



Matthew P. Jacobson, Ph.D.

Co-Founder, SAB Member



R. Scott Lokey, Ph.D.

Co-Founder



Further reading

Title
Author
Link
Type
Date

Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators. - PubMed - NCBI

pubmeddev, Boehm M , et al.

Web



Peptide Therapeutics Near the Sweetest Spots



Web

March 29, 2018

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services
+ Add new row

References